Doximity’s (NYSE:DOCS) Q2 CY2026: Beats On Revenue

Medical professional network Doximity (NYSE:DOCS) reported Q2 CY2026 results exceeding the market’s revenue expectations , with sales up 7.3% year on year to $156.6 million. The company expects next quarter’s revenue to be around $170.5 million, close to analysts’ estimates. Its non-GAAP profit of $0.29 per share was 4.2% below analysts’ consensus estimates.
Is now the time to buy Doximity? Find out in our full research report.
Doximity (DOCS) Q2 CY2026 Highlights:
Revenue: $156.6 million vs analyst estimates of $151.3 million (7.3% year-on-year growth, 3.5% beat)
Adjusted EPS: $0.29 vs analyst expectations of $0.30 (4.2% miss)
Adjusted EBITDA: $74.77 million vs analyst estimates of $69.59 million (47.7% margin, 7.4% beat)
The company slightly lifted its revenue guidance for the full year to $676 million at the midpoint from $670 million
EBITDA guidance for the full year is $319 million at the midpoint, below analyst estimates of $329.2 million
Operating Margin: 21.5%, down from 37.4% in the same quarter last year
Free Cash Flow Margin: 25.3%, down from 73.8% in the previous quarter
Billings: $159.3 million at quarter end, up 7% year on year
Market Capitalization: $3.89 billion
Company Overview
With over 80% of U.S. physicians as members of its digital community, Doximity (NYSE:DOCS) operates a digital platform that enables physicians and other healthcare professionals to collaborate, stay current with medical news, manage their careers, and conduct virtual patient visits.
Revenue Growth
Examining a company’s long-term performance can provide clues about its quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Luckily, Doximity’s sales grew at a decent 21.9% compounded annual growth rate over the last five years. Its growth was slightly above the average software company and shows its offerings resonate with customers.
Long-term growth is the most important, but within software, a half-decade historical view may miss new innovations or demand cycles. Doximity’s annualized revenue growth of 15.2% over the last two years is below its five-year trend, but we still think the results were respectable.
This quarter, Doximity reported year-on-year revenue growth of 7.3%, and its $156.6 million of revenue exceeded Wall Street’s estimates by 3.5%. Company management is currently guiding for a 1.2% year-on-year increase in sales next quarter.
Looking further ahead, sell-side analysts expect revenue to grow 3.6% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will face some demand challenges. At least the company is tracking well in other measures of financial health.